Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 23 of 25

COMPLETED Phase 4

A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir

NCT00148785

COMPLETED

Single Ventricle Outcome

NCT00308217

COMPLETED

Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation

NCT00142194

COMPLETED Phase 4

Kaletra Sex/Gender Pharmacokinetics (PK) Study

NCT00148759

COMPLETED Phase 2

Calcium and Vitamin D vs Markers of Adenomatous Polyps

NCT00208793

COMPLETED

Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease

NCT01369160

COMPLETED NA

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447

COMPLETED

Quality of Life in Pediatric Transplant Recipients

NCT00209196

COMPLETED

Bipolar Disorder (BPD) in Pregnancy: Predictors of Morbidity

NCT00864370

TERMINATED Phase 1

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

NCT00793650

TERMINATED

Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation

NCT00243802

TERMINATED Phase 3

Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery

NCT00166127

COMPLETED NA

Education and Supportive Partners Improving Self-Care (ENSPIRE)

NCT00166049

COMPLETED Phase 2

Mindfulness Meditation in Bone Marrow Transplantation

NCT00165282

TERMINATED NA

Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

NCT00209131

TERMINATED NA

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

NCT00209027

COMPLETED Phase 2

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

NCT00590317

COMPLETED Phase 2

Effect of Valsartan on Carotid Artery Disease

NCT00208767

COMPLETED Phase 3

HIV Prevention for African American Teens

NCT00279799

COMPLETED

Characterizing Psychological Consequences of Childhood Trauma

NCT00209105

COMPLETED

Thrombin Generation in Neonates

NCT00165906

COMPLETED Phase 4

Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts

NCT00165958

COMPLETED

Dietary Effects of Sulfur Amino Acids

NCT00228618

COMPLETED

Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics

NCT00615706

COMPLETED Phase 2

Effect of a Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and Endothelial Progenitor Cells (EPC's)

NCT00166088

COMPLETED NA

An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall

NCT00208871

COMPLETED Phase 2

A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving

NCT00208858

COMPLETED Early Phase 1

Effects of Tetrahydrobiopterin on Blood Pressure

NCT00208780

TERMINATED

Rhythm Disturbances After Ventricular Septal Defects

NCT00208624

COMPLETED NA

Spironolactone in Patients With Single Ventricle Heart

NCT00211081

COMPLETED

A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods

NCT00253019

COMPLETED

Mechanisms of Adaptation in Human Short Bowel Syndrome

NCT00248573

COMPLETED Phase 1

Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.

NCT00209144

COMPLETED Phase 2

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

NCT00166036

COMPLETED

Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease

NCT00101517

TERMINATED Phase 2

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

NCT00209079

COMPLETED NA

Motivating HIV+ Women: Risk Reduction and ART Adherence

NCT00253045

COMPLETED Phase 4

Intravenous (IV) Pantoprazole in Erosive Esophagitis

NCT00133770

COMPLETED Phase 3

Improving Primary Care in Patients With Mental Disorders

NCT00183313

COMPLETED

Ventricular Synchrony in Pediatric Patients

NCT00165932

COMPLETED

Resynchronization Therapy in Young Patients With and Without CHD

NCT00208806

COMPLETED

4-D Visualization Using Magnetic Resonance Imaging (MRI) in the Congenital Heart Disease Population

NCT00165945

COMPLETED Phase 4

Depression-Diabetes Mechanisms: Urban African Americans

NCT00209170

TERMINATED

Heart Failure in Adult Patients With a History of Congenital Heart Disease

NCT00208754

COMPLETED Phase 1

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

NCT00133822

TERMINATED NA

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

NCT00228813

COMPLETED

Understanding Pediatric Chest Pain and Other Symptoms

NCT00166231

COMPLETED Phase 4

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023

COMPLETED NA

A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease

NCT00208832

COMPLETED NA

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

NCT00753142

← Previous Page 23 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.